Parkinson's Disease Psychosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease Psychosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Parkinson's Disease Psychosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Parkinson's Disease Psychosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Psychosis Market.

The Parkinson's Disease Psychosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Parkinson's Disease Psychosis Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Parkinson's Disease Psychosis treatment therapies with a considerable amount of success over the years.
• Parkinson's Disease Psychosis companies working in the treatment market are Vanda Pharmaceuticals, Kyowa Kirin, Inc., Sage Therapeutics, Athira Pharma, Aptinyx, Tasly Pharmaceutical, Johns Hopkins University, and others, are developing therapies for the Parkinson's Disease Psychosis treatment
• Emerging Parkinson's Disease Psychosis therapies in the different phases of clinical trials are- Iloperidone, Istradefylline, SAGE-718, ATH-1017, NYX-458, pimavanserin tartrate, AGB101, and others are expected to have a significant impact on the Parkinson's Disease Psychosis market in the coming years.
• In October 2024, Adaptive Research, an organization focused on broadening access to clinical trials, has announced its involvement in an innovative decentralized Parkinson's disease study sponsored by PhotoPharmics Inc. The California Movement Disorders Center, a member of Adaptive Research's network, will act as a site for the LIGHT-PD trial, which evaluates the effectiveness of Celeste® Specialized Phototherapy in managing Parkinson's symptoms.
• In September 2024, AbbVie's newly acquired Parkinson's disease treatment candidate, tavapadon, demonstrated a significant reduction in disease burden during a Phase III trial. The TEMPO-1 Phase III study (NCT04201093) assessed tavapadon at daily doses of 5mg and 15mg. The trial achieved its primary endpoint, with both dosing groups showing superior improvements compared to placebo at week 26, based on a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Parkinson's Disease Psychosis Overview
Parkinson's disease psychosis (PDP) is a condition in which individuals with Parkinson's disease experience symptoms such as hallucinations, delusions, and confusion. It is a common non-motor symptom of Parkinson's disease, often occurring in the later stages of the disease. Hallucinations may involve seeing, hearing, or feeling things that are not present, while delusions can include false beliefs, such as thinking someone is plotting against them. PDP can be distressing for both the patient and their caregivers. It is typically managed with medications that target the underlying symptoms while balancing the side effects of Parkinson's disease treatment.

Get a Free Sample PDF Report to know more about Parkinson's Disease Psychosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Parkinson's Disease Psychosis Drugs Under Different Phases of Clinical Development Include:
• Iloperidone: Vanda Pharmaceuticals
• Istradefylline: Kyowa Kirin, Inc.
• SAGE-718: Sage Therapeutics
• ATH-1017: Athira Pharma
• NYX-458: Aptinyx
• pimavanserin tartrate: Tasly Pharmaceutical
• AGB101: Johns Hopkins University

Parkinson's Disease Psychosis Route of Administration
Parkinson's Disease Psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Parkinson's Disease Psychosis Molecule Type
Parkinson's Disease Psychosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Parkinson's Disease Psychosis Pipeline Therapeutics Assessment
• Parkinson's Disease Psychosis Assessment by Product Type
• Parkinson's Disease Psychosis By Stage and Product Type
• Parkinson's Disease Psychosis Assessment by Route of Administration
• Parkinson's Disease Psychosis By Stage and Route of Administration
• Parkinson's Disease Psychosis Assessment by Molecule Type
• Parkinson's Disease Psychosis by Stage and Molecule Type

DelveInsight's Parkinson's Disease Psychosis Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Parkinson's Disease Psychosis product details are provided in the report. Download the Parkinson's Disease Psychosis pipeline report to learn more about the emerging Parkinson's Disease Psychosis therapies at:
https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Parkinson's Disease Psychosis Therapeutics Market include:
Key companies developing therapies for Parkinson's Disease Psychosis are - Athira Pharma, Aptinyx, CogState Ltd., AgeneBio, 1ST Biotherapeutics, Inc., ACADIA Pharmaceuticals Inc., Vanda Pharmaceuticals, Kyowa Kirin, Inc., Sage Therapeutics, BrainX Corporation, CuraSen Therapeutics, Inc., and others.

Parkinson's Disease Psychosis Pipeline Analysis:
The Parkinson's Disease Psychosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease Psychosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Psychosis Treatment.
• Parkinson's Disease Psychosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson's Disease Psychosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease Psychosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Parkinson's Disease Psychosis drugs and therapies-
https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Psychosis Pipeline Market Strengths
• Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
• The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm

Parkinson's Disease Psychosis Pipeline Market Opportunities
• There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
• Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments

Scope of Parkinson's Disease Psychosis Pipeline Drug Insight
• Coverage: Global
• Key Parkinson's Disease Psychosis Companies: Vanda Pharmaceuticals, Kyowa Kirin, Inc., Sage Therapeutics, Athira Pharma, Aptinyx, Tasly Pharmaceutical, Johns Hopkins University, and others
• Key Parkinson's Disease Psychosis Therapies: Iloperidone, Istradefylline, SAGE-718, ATH-1017, NYX-458, pimavanserin tartrate, AGB101, and others
• Parkinson's Disease Psychosis Therapeutic Assessment: Parkinson's Disease Psychosis current marketed and Parkinson's Disease Psychosis emerging therapies
• Parkinson's Disease Psychosis Market Dynamics: Parkinson's Disease Psychosis market drivers and Parkinson's Disease Psychosis market barriers

Request for Sample PDF Report for Parkinson's Disease Psychosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Parkinson's Disease Psychosis Report Introduction
2. Parkinson's Disease Psychosis Executive Summary
3. Parkinson's Disease Psychosis Overview
4. Parkinson's Disease Psychosis- Analytical Perspective In-depth Commercial Assessment
5. Parkinson's Disease Psychosis Pipeline Therapeutics
6. Parkinson's Disease Psychosis Late Stage Products (Phase II/III)
7. Parkinson's Disease Psychosis Mid Stage Products (Phase II)
8. Parkinson's Disease Psychosis Early Stage Products (Phase I)
9. Parkinson's Disease Psychosis Preclinical Stage Products
10. Parkinson's Disease Psychosis Therapeutics Assessment
11. Parkinson's Disease Psychosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Parkinson's Disease Psychosis Key Companies
14. Parkinson's Disease Psychosis Key Products
15. Parkinson's Disease Psychosis Unmet Needs
16 . Parkinson's Disease Psychosis Market Drivers and Barriers
17. Parkinson's Disease Psychosis Future Perspectives and Conclusion
18. Parkinson's Disease Psychosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Parkinson's Disease Psychosis Market https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Parkinson's Disease Psychosis Epidemiology https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease Psychosis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market
• Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market
• Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.